Male, 73 years old, was admitted to the hospital on 2013-10-30 for “1 week of epigastric pain and discomfort”, AFP 527ng/ml, 45 days after the first intervention, AFP was normal, 4 months after the second intervention, AFP was normal. Intervention can be the preferred method in non-surgical treatment. Indications: (1) The main indications of TACE are middle and advanced hepatocellular carcinoma and metastatic carcinoma that cannot be surgically resected, including: (1) macroscopic hepatocellular carcinoma: the proportion of tumor occupying the whole liver is less than 70%; (relative) (2) multiple nodular hepatocellular carcinoma; (3) failure of surgical operation or postoperative recurrence; (4) bleeding from rupture of hepatocellular carcinoma and bleeding from portal hypertension caused by hepatic artery-portal vein shunt. (2) Applied before hepatic tumor resection, it can shrink the tumor, which is conducive to second-stage resection, and at the same time can clarify the number of lesions; (3) Small hepatocellular carcinoma, but those who are unsuitable for or unwilling to undergo surgical, radiofrequency or microwave ablation treatment; (4) Controlling the local pain and bleeding as well as embolizing arterial vein impotence; (5) Preventing recurrence after resection of hepatocellular carcinoma.